CLAIMS

What is claimed is:

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is independently selected from:

C_5 or C_6 cycloalkyl-(C_1-C_8 alkylenyl);

Substituted C_5 or C_6 cycloalkyl-(C_1-C_8 alkylenyl);

C_8-C_{10} bicycloalkyl-(C_1-C_8 alkylenyl);

Substituted C_8-C_{10} bicycloalkyl-(C_1-C_8 alkylenyl);

5- or 6-membered heterocycloalkyl-(C_1-C_8 alkylenyl);

Substituted 5- or 6-membered heterocycloalkyl-(C_1-C_8 alkylenyl);

8- to 10-membered heterobicycloalkyl-(C_1-C_8 alkylenyl);

Substituted 8- to 10-membered heterobicycloalkyl-(C_1-C_8 alkylenyl);

Phenyl-(C_1-C_8 alkylenyl);

Substituted phenyl-(C_1-C_8 alkylenyl);

Naphthyl-(C_1-C_8 alkylenyl);

Substituted naphthyl-(C_1-C_8 alkylenyl);

5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

Substituted 5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Substituted 8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Phenyl;

Substituted phenyl;

Naphthyl;

Substituted naphthyl;

5- or 6-membered heteroaryl;

Substituted 5- or 6-membered heteroaryl;

8- to 10-membered heterobiaryl; and

Substituted 8- to 10-membered heterobiaryl;

R^2 is independently selected from:

H;

C_1-C_6 alkyl;

Phenyl-(C_1-C_8 alkylenyl);

Substituted phenyl-(C_1-C_8 alkylenyl);

Naphthyl-(C_1-C_8 alkylenyl);

Substituted naphthyl-(C_1-C_8 alkylenyl);

5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

Substituted 5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Substituted 8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Phenyl-O-(C_1-C_8 alkylenyl);

Substituted phenyl-O-(C_1-C_8 alkylenyl);

Phenyl-S-(C_1-C_8 alkylenyl);

Substituted phenyl-S-(C_1-C_8 alkylenyl);

Phenyl-S(O)-(C_1-C_8 alkylenyl);

Substituted phenyl-S(O)-(C_1-C_8 alkylenyl);

Phenyl-$S(O)_2$-(C_1-C_8 alkylenyl); and

Substituted phenyl-$S(O)_2$-(C_1-C_8 alkylenyl);

Each substituted R^1 and R^2 group contains from 1 to 4 substituents, each independently on a carbon or nitrogen atom, independently selected from:

C_1-C_6 alkyl;

CN;

CF_3;

HO;

(C_1-C_6 alkyl)-O;

$(C_1\text{-}C_6$ alkyl)-$S(O)_2$;

H_2N;

$(C_1\text{-}C_6$ alkyl)-N(H);

$(C_1\text{-}C_6$ alkyl)$_2$-N;

$(C_1\text{-}C_6$ alkyl)-C(O)O-$(C_1\text{-}C_8$ alkylenyl)$_m$;

$(C_1\text{-}C_6$ alkyl)-C(O)O-(1- to 8-membered heteroalkylenyl)$_m$;

$(C_1\text{-}C_6$ alkyl)-C(O)N(H)-$(C_1\text{-}C_8$ alkylenyl)$_m$;

$(C_1\text{-}C_6$ alkyl)-C(O)N(H)-(1- to 8-membered heteroalkylenyl)$_m$;

$H_2NS(O)_2$-$(C_1\text{-}C_8$ alkylenyl);

$(C_1\text{-}C_6$ alkyl)-N(H)$S(O)_2$-$(C_1\text{-}C_8$ alkylenyl)$_m$;

$(C_1\text{-}C_6$ alkyl)$_2$-$NS(O)_2$-$(C_1\text{-}C_8$ alkylenyl)$_m$;

3- to 6-membered heterocycloalkyl-$(G)_m$;

Substituted 3- to 6-membered heterocycloalkyl-$(G)_m$;

5- or 6-membered heteroaryl-$(G)_m$;

Substituted 5- or 6-membered heteroaryl-$(G)_m$;

$(C_1\text{-}C_6$ alkyl)-$S(O)_2$-N(H)-C(O)-$(C_1\text{-}C_8$ alkylenyl)$_m$; and

$(C_1\text{-}C_6$ alkyl)-C(O)-N(H)-$S(O)_2$-$(C_1\text{-}C_8$ alkylenyl)$_m$;

wherein each substituent on a carbon atom may further be independently selected from:

Halo; and

HO_2C;

wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C(=O);

wherein two adjacent, substantially sp^2 carbon atoms may be taken together with a diradical substituent to form a cyclic diradical selected from:




;

;

;

;

;

;

;

;

;

; and

;

R is H or C_1-C_6 alkyl;

G is CH_2; O, S, S(O); or $S(O)_2$;

m is an integer of 0 or 1;

Y^3 and Y^4 are taken together to form a diradical group selected from:


;

;

;


; and

;

R^3 is H or HO;

U^5, U^6, and U^8 are each C(H); or

One of U^5, U^6, and U^8 is C-R^4 or N and the other two of U^5, U^6, and U^8 are each C(H);

R^4 is independently selected from the groups:

H;

F;

Cl;

CH_3;

CH_3O;

$CH=CH_2$;

HO;

CF_3; and

CN;

Q is selected from:

OC(O);

$CH(R^6)C(O)$;

$OC(NR^6)$;

$CH(R^6)C(NR^6)$;

$N(R^6)C(O)$;

$N(R^6)C(S)$;

$N(R^6)C(NR^6)$;

$N(R^6)CH_2$;

SC(O);

$CH(R^6)C(S)$;

$SC(NR^6)$;

trans-(H)C=C(H);

cis-(H)C=C(H);

C≡C;

$CH_2C≡C$;

$C≡CCH_2$;

$CF_2C≡C$; and

$C{\equiv}CCF_2$;


;


;


;


;


;


; and


;

Each R^6 independently is H, C_1-C_6 alkyl, C_3-C_6 cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; benzyl; or 5- or 6-membered heteroaryl;

X is O, S, N(H), or N(C_1-C_6 alkyl);

Each V is independently C(H) or N;

wherein each C_8-C_{10} bicycloalkyl is a bicyclic carbocyclic ring that contains 8-, 9-, or 10-member carbon atoms which are 5,5-fused, 6,5-fused, or 6,6-fused bicyclic rings, respectively, and wherein the ring is saturated or optionally contains one carbon-carbon double bond;

wherein each 8- to 10-membered heterobicycloalkyl is a bicyclic ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 $S(O)_2$, 1 N, 4 N(H), and 4 N(C_1-C_6 alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond, and wherein the heterobicycloalkyl is a 5,5-fused, 6,5-fused, or 6,6-fused bicyclic ring, respectively,

wherein each heterocycloalkyl is a ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 $S(O)_2$, 1 N, 4 N(H), and 4 N(C_1-C_6 alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one

S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond;

wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C_1-C_6 alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N, N(H), and N(C_1-C_6 alkyl), and 5- and 6-membered heteroaryl are monocyclic rings;

wherein each heterobiaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C_1-C_6 alkyl), and 4 N, and where the 8-, 9-, and 10-membered heterobiaryl are 5,5-fused, 6,5-fused, and 6,6-fused bicyclic rings, respectively, and wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each other;

wherein with any (C_1-C_6 alkyl)$_2$-N group, the C_1-C_6 alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and

wherein each group and each substituent recited above is independently selected.

2. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is N(R^6)C(O).

3. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is C≡C.

4. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y^3 and Y^4 are taken together to form a diradical group selected from:



.

5. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y^3 and Y^4 are taken together to form a diradical group selected from:



6. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y^3 and Y^4 are taken together to form a diradical group selected from:



7. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Y^3 and Y^4 are taken together to form a diradical group selected from:



8. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is OH.

9. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is H.

10. The compound according to any one of Claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^1 is independently selected from:

Phenyl-(C_1-C_8 alkylenyl);

Substituted phenyl-(C_1-C_8 alkylenyl);

5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

Substituted 5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl); and

Substituted 8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl); and

R^2 is independently selected from:

Phenyl-(C_1-C_8 alkylenyl)$_m$;

Substituted phenyl-(C_1-C_8 alkylenyl)$_m$;

5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl)$_m$;

Substituted 5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl)$_m$;

8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl)$_m$; and

Substituted 8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl)$_m$;

wherein m is an integer of 0 or 1; and

11. A compound of Formula XIV



XIV

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is independently selected from:

C_5 or C_6 cycloalkyl-(C_1-C_8 alkylenyl);

Substituted C_5 or C_6 cycloalkyl-(C_1-C_8 alkylenyl);

C_8-C_{10} bicycloalkyl-(C_1-C_8 alkylenyl);

Substituted C_8-C_{10} bicycloalkyl-(C_1-C_8 alkylenyl);

5- or 6-membered heterocycloalkyl-(C_1-C_8 alkylenyl);

Substituted 5- or 6-membered heterocycloalkyl-(C_1-C_8 alkylenyl);

8- to 10-membered heterobicycloalkyl-(C_1-C_8 alkylenyl);

Substituted 8- to 10-membered heterobicycloalkyl-(C_1-C_8 alkylenyl);

Phenyl-(C_1-C_8 alkylenyl);

Substituted phenyl-(C_1-C_8 alkylenyl);

Naphthyl-(C_1-C_8 alkylenyl);

Substituted naphthyl-(C_1-C_8 alkylenyl);

5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

Substituted 5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Substituted 8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Phenyl;

Substituted phenyl;

Naphthyl;

Substituted naphthyl;

5- or 6-membered heteroaryl;

Substituted 5- or 6-membered heteroaryl;

8- to 10-membered heterobiaryl; and

Substituted 8- to 10-membered heterobiaryl;

R^2 is independently selected from:

H;

C_1-C_6 alkyl;

Phenyl-(C_1-C_8 alkylenyl);

Substituted phenyl-(C_1-C_8 alkylenyl);

Naphthyl-(C_1-C_8 alkylenyl);

Substituted naphthyl-(C_1-C_8 alkylenyl);

5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

Substituted 5- or 6-membered heteroaryl-(C_1-C_8 alkylenyl);

8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Substituted 8- to 10-membered heterobiaryl-(C_1-C_8 alkylenyl);

Phenyl-O-(C_1-C_8 alkylenyl);

Substituted phenyl-O-(C_1-C_8 alkylenyl);

Phenyl-S-(C_1-C_8 alkylenyl);

Substituted phenyl-S-(C_1-C_8 alkylenyl);

Phenyl-S(O)-(C_1-C_8 alkylenyl);

Substituted phenyl-S(O)-(C_1-C_8 alkylenyl);

Phenyl-$S(O)_2$-(C_1-C_8 alkylenyl); and

Substituted phenyl-$S(O)_2$-(C_1-C_8 alkylenyl);

Each substituted R^1 and R^2 group contains from 1 to 4 substituents, each independently on a carbon or nitrogen atom, independently selected from:

C_1-C_6 alkyl;

CN;

CF_3;

HO;

(C_1-C_6 alkyl)-O;

(C_1-C_6 alkyl)-$S(O)_2$;

H_2N;

(C_1-C_6 alkyl)-N(H);

(C_1-C_6 alkyl)$_2$-N;

(C_1-C_6 alkyl)-C(O)O-(C_1-C_8 alkylenyl)$_m$;

(C_1-C_6 alkyl)-C(O)O-(1- to 8-membered heteroalkylenyl)$_m$;

(C_1-C_6 alkyl)-C(O)N(H)-(C_1-C_8 alkylenyl)$_m$;

(C_1-C_6 alkyl)-C(O)N(H)-(1- to 8-membered heteroalkylenyl)$_m$;

$H_2NS(O)_2$-(C_1-C_8 alkylenyl);

(C_1-C_6 alkyl)-N(H)$S(O)_2$-(C_1-C_8 alkylenyl)$_m$;

(C_1-C_6 alkyl)$_2$-$NS(O)_2$-(C_1-C_8 alkylenyl)$_m$;

3- to 6-membered heterocycloalkyl-(G)$_m$;

Substituted 3- to 6-membered heterocycloalkyl-(G)$_m$;

5- or 6-membered heteroaryl-(G)$_m$;

Substituted 5- or 6-membered heteroaryl-(G)$_m$;

(C_1-C_6 alkyl)-$S(O)_2$-N(H)-C(O)-(C_1-C_8 alkylenyl)$_m$; and

(C_1-C_6 alkyl)-C(O)-N(H)-$S(O)_2$-(C_1-C_8 alkylenyl)$_m$;

wherein each substituent on a carbon atom may further be independently selected from:

Halo; and

HO_2C;

wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C(=O);

wherein two adjacent, substantially sp^2 carbon atoms may be taken together with a diradical substituent to form a cyclic diradical selected from:



; and ;

R is H or C_1-C_6 alkyl;

G is CH_2; O, S, S(O); or $S(O)_2$;

m is an integer of 0 or 1;

wherein each C_8-C_{10} bicycloalkyl is a bicyclic carbocyclic ring that contains 8-, 9-, or 10-member carbon atoms which are 5,5-fused, 6,5-fused, or 6,6-

fused bicyclic rings, respectively, and wherein the ring is saturated or optionally contains one carbon-carbon double bond;

wherein each 8- to 10-membered heterobicycloalkyl is a bicyclic ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 $S(O)_2$, 1 N, 4 N(H), and 4 $N(C_1$-C_6 alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond, and wherein the heterobicycloalkyl is a 5,5-fused, 6,5-fused, or 6,6-fused bicyclic ring, respectively,

wherein each heterocycloalkyl is a ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 $S(O)_2$, 1 N, 4 N(H), and 4 $N(C_1$-C_6 alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond;

wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 $N(C_1$-C_6 alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N, N(H), and $N(C_1$-C_6 alkyl), and 5- and 6-membered heteroaryl are monocyclic rings;

wherein each heterobiaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 $N(C_1$-C_6 alkyl), and 4 N, and where the 8-, 9-, and 10-membered heterobiaryl are 5,5-fused, 6,5-fused, and 6,6-fused bicyclic rings, respectively, and wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each other;

wherein with any $(C_1$-C_6 alkyl$)_2$-N group, the C_1-C_6 alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and

wherein each group and each substituent recited above is independently selected.

12. The compound according to Claim 11, selected from:

4-(6-Benzylcarbamoyl-4-hydroxy-quinolin-3-ylmethyl)-benzoic acid;

4-[4-Hydroxy-6-(4-methoxy-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-[4-Hydroxy-6-(3-methoxy-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-{4-Hydroxy-6-[(2-methoxy-pyridin-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(pyridin-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(pyridin-3-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-[6-(4-Cyano-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid;

4-[4-Hydroxy-6-(4-methyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-[4-Hydroxy-6-(4-trifluoromethyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-[6-(4-Fluoro-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid;

4-[6-(4-Chloro-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid;

4-[6-(4-Bromo-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid;

4-[4-Hydroxy-6-(4-iodo-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-[4-Hydroxy-6-(4-methanesulfonyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-[4-Hydroxy-6-(4-sulfo-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-[4-Hydroxy-6-(4-sulfamoyl-benzylcarbamoyl)-quinolin-3-ylmethyl]-benzoic acid;

4-[6-(4-Dimethylsulfamoyl-benzylcarbamoyl)-4-hydroxy-quinolin-3-ylmethyl]-benzoic acid;

4-{6-[4-(Aziridine-1-sulfonyl)-benzylcarbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid;

or a pharmaceutically acceptable salt thereof.

13. The compound according to Claim 11, selected from:

4-{4-Hydroxy-6-[(piperidin-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(4-methyl-piperazin-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(morpholin-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(pyrrolidin-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(pyrrol-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(imidazol-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[([1,2,4]triazol-4-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(tetrazol-1-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{6-[(2,3-Dihydro-benzo[b]furan-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid;

4-{6-[(2,3-Dihydro-benzo[b]thiophen-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid;

4-{6-[(2,3-Dihydro-1H-indol-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid;

4-{4-Hydroxy-6-[(1H-indol-5-ylmethyl)-carbamoyl]-quinolin-3-ylmethyl}-benzoic acid;

4-{6-[(Benzo[b]thiophen-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid;

4-{6-[(Benzofuran-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid; and

4-{6-[(Benzooxazol-5-ylmethyl)-carbamoyl]-4-hydroxy-quinolin-3-ylmethyl}-benzoic acid;

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition, comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.

15. The pharmaceutical composition according to Claim 14, comprising a compound according to Claim 12 or 13, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.

16. A method for treating osteoarthritis or rheumatoid arthritis, comprising administering to a patient suffering from osteoarthritis or rheumatoid arthritis a nontoxic effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

17. The method according to Claim 16, wherein the compound administered is a compound according to Claim 12 or 13, or a pharmaceutically acceptable salt thereof.